塞利尼索剂量调整在经治多发性骨髓瘤中的治疗优化与定位
本文是对BOSTON试验亚组分析的评论,聚焦来那度胺难治性多发性骨髓瘤患者。亚组分析显示,塞利尼索减量较全剂量显著提高总缓解率(74.3% vs. 55.6%)、加深缓解(≥VGPR 48.6% vs. 11.1%)、延长缓解持续时间(15.3 vs. 4.2个月)、至下次治疗时间(14.8 vs. 4.8个月)和无进展生存期(13.9 vs. 5.1个月),并改善耐受性和生活质量。
要点
- 来那度胺难治性骨髓瘤中,塞利尼索减量较全剂量显著改善疗效结局。
- 减量后非血液学不良事件(恶心、乏力、腹泻、食欲下降、呕吐)明显减少。
- 减量组生活质量改善超过全剂量组两倍,且超过10分临床意义阈值。
核心结论
- 在来那度胺难治性多发性骨髓瘤患者中,塞利尼索减量较全剂量显著改善疗效、耐受性和生活质量。
研究设计与样本
- 本文为对BOSTON试验亚组分析的评论,该亚组分析纳入来那度胺难治性多发性骨髓瘤患者,比较塞利尼索减量与全剂量的结局。
主要发现
- 塞利尼索减量组总缓解率为74.3%,全剂量组为55.6%。
- 减量组≥VGPR率为48.6%,全剂量组为11.1%。
- 减量组缓解持续时间为15.3个月,全剂量组为4.2个月。
- 减量组至下次治疗时间为14.8个月,全剂量组为4.8个月。
- 减量组无进展生存期为13.9个月,全剂量组为5.1个月。
关键数值与推荐
- 首次塞利尼索减量后,恶心、乏力、腹泻、食欲下降和呕吐等非血液学不良事件均明显减少。
- 减量组全球健康状况生活质量改善幅度超过全剂量组两倍,减量后超过10分临床意义改善阈值。
临床怎么用
- 对来那度胺难治性多发性骨髓瘤患者,可考虑塞利尼索减量以改善疗效、耐受性和生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with lenalidomide-refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs. 11.1%), longer duration of response (15.3 vs. 4.2 months), longer time to next treatment (14.8 vs. 4.8 months) and longer progression-free survival (13.9 months vs. 5.1 months). Selinexor dose reduction further improved tolerability, enabling longer treatment duration, with non-haematological adverse events such as nausea, fatigue, diarrhoea, decreased appetite and vomiting all decreased meaningfully after the first SEL dose reduction. Quality of life improved meaningfully also: global health status quality assessed via European Organization for Research and Treatment of Cancer Quality of Life Questionnaire improved more than twice as much in the SEL-reduced group versus the full-dose group, with the dose-reduced patients exceeding the clinically meaningful 10-point improvement threshold after dose reduction. Commentary on: Delimpasi et al. Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial. Br J Haematol 2026; 208:2260-2264.
引用
- Baljevic M. Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma. Br J Haematol. 2026. PMID: 42481431. doi:10.1111/bjh.70711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。